Human epidermal growth factor receptor-2 (HER2) is overexpressed in 20–30% of breast cancer and is associated with aggressive tumors, a high rate of metastasis, and poor prognosis [11,12]. This evidence concerns the gene ERBB2 and breast carcinoma.